DMC Research Center

Dong-A ST is a prominent South Korean pharmaceutical company that specializes in the discovery, development, and commercialization of ethical drugs, over-the-counter medicines, and medical devices. The company's research and development activities are primarily conducted at its DMC Research Center in Yongin, which serves as the innovation hub for the Dong-A Socio Group. Dong-A ST maintains a robust clinical pipeline focused on metabolic diseases, urology, and immunology, with lead candidates such as DA-1241 for MASH and DA-1726 for obesity. In addition to its proprietary drug development, the company is a significant player in the biosimilars market and operates through numerous global partnerships to expand its geographic reach. Dong-A ST is publicly traded on the Korea Stock Exchange and continues to leverage its integrated manufacturing capabilities to support its diverse product portfolio.